Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for women with Hard-to-Treat uterine cancer?

NCT ID NCT04814108

Disease control Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called ZN-c3 (azenosertib) in 92 women with a rare and aggressive type of uterine cancer that had come back or not responded to standard treatments. The goal was to see if the drug could shrink tumors and to check its safety. The drug is taken as a pill and works by blocking a protein that helps cancer cells grow.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ZN-c3 (azenosertib)
What this could lead to
If successful, this could provide a new treatment option for women with uterine serous carcinoma that has returned or not responded to other therapies.
What could go wrong
This is a Phase 2 trial with only 92 participants, so results are preliminary. The drug may not work for everyone and could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

92 people

The number who actually took part.

Started

Jul 2021

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA 1. Females ≥18 years of age at the time of informed consent. 2. Histologically confirmed recurrent or persistent USC for which no other proven effective treatment options are available or any available standard of care therapy was not tolerated or was refused by the subject. * Subjects with endometrial carcinoma of mixed histology where the serous component comprises at least 5% of the tumor will be considered eligible. * Subjects with carcinosarcomas (even if there is a serous component) are not eligible. 3. Measurable disease per RECIST Guideline Version 1.1 4. Required prior therapy for endometrial cancer: 1. Treatment with a platinum-based chemotherapy regimen. 2. Treatment with a PD-(L)1 inhibitor 3. Known HER2-positive tumors: Treatment with at least 1 HER2-targeted therapy, except for subjects who are not clinically eligible. 5. Adequate hematologic and organ function EXCLUSION CRITERIA 1. Any of the following treatment interventions within the specified time frame prior to C1D1: 1. Major surgery within 28 days 2. Any chemotherapy or targeted tumor therapy within 14 days or 5 half-lives (whichever is shorter). 3. Radiation therapy within 21 days; 4. Autologous or allogeneic stem cell transplant within 3 months. 5. Current use of any other investigational drug therapy \<28 days or 5 half-lives (whichever is shorter). 2. Prior therapy with ZN-c3 or any other WEE1 inhibitor, ATR inhibitor, or CHK1/2 inhibitor for USC. 3. A serious illness or medical condition(s) including, but not limited to: Any evidence of bowel obstruction as determined by air/fluid levels on computed tomography (CT) scan, recent hospitalization for bowel obstruction within 3 months prior to C1D1, or recurrent paracentesis or thoracentesis within 6 weeks prior to C1D1.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Uterine serous carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cystadenocarcinoma, Serous endometrial serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Uterine serous carcinoma

Contacts and locations

Locations

  • Acad. Fridon Todua Medical Center

    Tbilisi, 0112, Georgia

  • Alaska Women's Cancer Care

    Anchorage, Alaska, 99508, United States

  • Arizona Oncology Associates Wilmot HOPE

    Tucson, Arizona, 85711, United States

  • Ascension St. Thomas Midtown Hospital

    Nashville, Tennessee, 37236, United States

  • Banner University Medical Center Tucson

    Tucson, Arizona, 85719, United States

  • Burnside War Memorial Hospital

    Toorak Gardens, South Australia, 6065, Australia

  • Cabrini Hospital Malvern

    Malvern, Victoria, 3144, Australia

  • Center of Hope

    Reno, Nevada, 89511, United States

  • Chu de Quebec-Universite

    Québec, Quebec, G1R 3S1, Canada

  • Concord Repatriation General Hospital

    Concord, New South Wales, 2139, Australia

  • Corewell Health

    Grand Rapids, Michigan, 49503, United States

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia, 30912, United States

  • HCA Midwest Health Kansas City Research

    Kansas City, Missouri, 64132, United States

  • Honor Health

    Phoenix, Arizona, 85016, United States

  • Icon Cancer Centre- Chermside

    Brisbane, Queensland, 4032, Australia

  • LTD High Technology Hospital Medcenter

    Batumi, Adjara, 6000, Georgia

  • LTD Innova Medical Center

    Tbilisi, 0144, Georgia

  • LTD TIM-Tbilisi Innova of Medicine

    Tbilisi, 0160, Georgia

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Maryland Oncology Hematology

    Annapolis, Maryland, 21401, United States

  • Mater Cancer Care Centre, Mater Misericordiae Limited

    Brisbane, Queensland, 4101, Australia

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Mount Sinai Medical Center

    Miami Beach, Florida, 33140, United States

  • Northern Cancer Institute

    St Leonards, New South Wales, 2065, Australia

  • Northside Hospital

    Atlanta, Georgia, 30342, United States

  • Northwest Cancer Specialists

    Portland, Oregon, 97227, United States

  • Northwestern University

    Evanston, Illinois, 60208, United States

  • Oakland Medical Group

    Detroit, Michigan, 48201, United States

  • Ohio State University James Cancer Hospital

    Columbus, Ohio, 43210, United States

  • Oncology Hematology Care

    Cincinnati, Ohio, 45242, United States

  • Optimum Clinical Research Group- Women's Oncology

    Albuquerque, New Mexico, 87109, United States

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • Providence Portland Medical Center

    Portland, Oregon, 97213, United States

  • Revive Clinical Research

    Sterling, Michigan, 48659, United States

  • Rustavi Clinic

    Rustavi, Kvemo Kartli, 3700, Georgia

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08901, United States

  • Sarasota Memorial Hospital

    Sarasota, Florida, 34239, United States

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, 6009, Australia

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, M4N 3M5, Canada

  • Temple University Hospital

    Philadelphia, Pennsylvania, 19140, United States

  • Texas Oncology Austin

    Austin, Texas, 78705, United States

  • Texas Oncology Fort Worth Cancer Center

    Fort Worth, Texas, 76104, United States

  • Texas Oncology Gulf Coast

    Houston, Texas, 77089, United States

  • Texas Oncology San Antonio

    San Antonio, Texas, 78240, United States

  • Trihealth Cancer Institute

    Cincinnati, Ohio, 45242, United States

  • University of California Irvine Medical Center

    Orange, California, 92868, United States

  • University of California San Francisco at Mission Bay

    San Francisco, California, 94158, United States

  • University of Cincinnati

    Cincinnati, Ohio, 45219, United States

  • University of Maryland Medical Center

    Baltimore, Maryland, 21201, United States

  • University of Oklahoma Peggy and Charles Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73104, United States

  • University of South Florida

    Tampa, Florida, 33606, United States

  • University of Virginia Cancer Center

    Charlottesville, Virginia, 22908, United States

  • VCU Health System

    Richmond, Virginia, 23298, United States

  • Virginia Cancer Specialists

    Warrenton, Virginia, 20186, United States

  • Westchester Medical Center

    Hawthorne, New York, 10532, United States

  • Willamette Valley Cancer Institute

    Eugene, Oregon, 97401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.